Labcorp Holdings Inc. ((LH)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: The study titled ‘Collection of Pregnancy Outcome Data and Whole Blood Samples From Women Undergoing Non-Invasive Screening for Early, Preterm, and Term Preeclampsia’ aims to evaluate the effectiveness of non-invasive screening methods for preeclampsia in pregnant women between 11-14 weeks of gestation. This research is significant as it seeks to improve early detection and management of preeclampsia, a condition that can lead to serious complications for both mother and child.
Intervention/Treatment: The study does not involve any specific intervention as it is observational. Blood samples will be collected from participants to assess preeclampsia risk, but results will not be shared with participants or their physicians. The focus is on comparing screening results with actual birth outcomes.
Study Design: This is an observational case-control study with a prospective time perspective. It involves collecting whole blood samples, which will be processed into plasma and serum, and in some cases, remnant placental tissue will be collected post-delivery. The primary aim is to gather data without any allocation or masking involved.
Study Timeline: The study began on October 14, 2024, with an estimated primary completion date yet to be determined. The latest update was submitted on June 11, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
Market Implications: Labcorp Holdings Inc. (LH), being a collaborator in this study, could see positive impacts on its stock performance due to its involvement in pioneering non-invasive screening methods for preeclampsia. This could enhance investor sentiment as the study addresses a critical healthcare need. Competitors in the diagnostics and prenatal care industry may also be closely monitoring these developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.